Clinical Scorecard: Efficacy Comparison of Postoperative Adjuvant Transcatheter Arterial Chemoembolization Versus Lenvatinib Combined with Tislelizumab in BCLC Stage 0-B Hepatocellular Carcinoma Patients Following Radical Resection

At a Glance

Key Highlights

• 614 patients evaluated for RFS and OS after radical resection.
• Both PA-TACE and PA-LT significantly improved RFS and OS compared to LR alone.
• No significant differences in RFS or OS between PA-TACE and PA-LT groups.
• Median RFS: 44.00 months (PA-TACE) vs. 40.50 months (PA-LT).
• Median OS: 69.00 months (PA-TACE) vs. 65.00 months (PA-LT).

Guideline-Based Recommendations

Diagnosis

• Histologically confirmed HCC with negative margins (R0 resection).
• Presence of at least one recurrence risk factor.

Management

• Consider PA-TACE or PA-LT for patients with high-risk recurrence factors post-resection.

Monitoring & Follow-up

• Regular follow-up for recurrence assessment in patients post radical resection.

Risks

• High recurrence rate of 50%–70% within 5 years after radical resection.

Patient & Prescribing Data

Patients with BCLC stage 0–B HCC and at least one high-risk recurrence factor.

Both PA-TACE and PA-LT have acceptable safety profiles with no severe adverse events reported.

Clinical Best Practices

• Utilize propensity score matching to enhance study robustness.
• Monitor for recurrence in patients with identified high-risk factors.

Related Resources & Content

• Study on HCC recurrence rates
• Lenvatinib and tislelizumab in unresectable HCC